Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company ISA Pharmaceuticals B.V.
DescriptionSynthetic long peptides targeting preferentially expressed antigen in melanoma (PRAME) conjugated to ISA's amplivant adjuvant
Molecular Target Preferentially expressed antigen in melanoma (PRAME)
Mechanism of ActionImmunotherapy
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPreclinical
Standard IndicationMelanoma
Indication DetailsTreat melanoma
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today